Foundation Medicine Inc (NASDAQ:FMI) CFO Jason Ryan sold 2,336 shares of the stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $64.00, for a total value of $149,504.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Jason Ryan also recently made the following trade(s):
- On Tuesday, December 5th, Jason Ryan sold 21,726 shares of Foundation Medicine stock. The shares were sold at an average price of $61.26, for a total value of $1,330,934.76.
- On Thursday, November 2nd, Jason Ryan sold 9,731 shares of Foundation Medicine stock. The shares were sold at an average price of $50.00, for a total value of $486,550.00.
- On Thursday, October 12th, Jason Ryan sold 1,152 shares of Foundation Medicine stock. The shares were sold at an average price of $45.05, for a total value of $51,897.60.
Shares of Foundation Medicine Inc (NASDAQ FMI) traded up $0.45 during trading on Wednesday, reaching $63.05. The company had a trading volume of 184,187 shares, compared to its average volume of 338,680. The stock has a market cap of $2,290.00, a P/E ratio of -14.11 and a beta of -0.01. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.03 and a current ratio of 2.24. Foundation Medicine Inc has a 1 year low of $17.10 and a 1 year high of $70.75.
FMI has been the subject of a number of recent analyst reports. Zacks Investment Research upgraded Foundation Medicine from a “hold” rating to a “buy” rating and set a $59.00 price target for the company in a research report on Monday, November 6th. BidaskClub raised Foundation Medicine from a “hold” rating to a “buy” rating in a research note on Saturday, September 9th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $45.33.
A number of institutional investors have recently made changes to their positions in the stock. Chevy Chase Trust Holdings Inc. lifted its stake in Foundation Medicine by 1.1% in the 3rd quarter. Chevy Chase Trust Holdings Inc. now owns 1,059,141 shares of the company’s stock worth $42,572,000 after acquiring an additional 11,934 shares in the last quarter. Discovery Group I LLC lifted its stake in Foundation Medicine by 0.9% in the 3rd quarter. Discovery Group I LLC now owns 836,986 shares of the company’s stock worth $33,647,000 after acquiring an additional 7,181 shares in the last quarter. Oppenheimer & Co. Inc. lifted its stake in Foundation Medicine by 5.8% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 723,480 shares of the company’s stock worth $29,084,000 after acquiring an additional 39,390 shares in the last quarter. Vanguard Group Inc. lifted its stake in Foundation Medicine by 8.2% in the 2nd quarter. Vanguard Group Inc. now owns 631,339 shares of the company’s stock worth $25,096,000 after acquiring an additional 47,843 shares in the last quarter. Finally, Lord Abbett & CO. LLC lifted its stake in Foundation Medicine by 146.0% in the 2nd quarter. Lord Abbett & CO. LLC now owns 579,225 shares of the company’s stock worth $23,024,000 after acquiring an additional 343,770 shares in the last quarter. 32.68% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “Foundation Medicine Inc (FMI) CFO Jason Ryan Sells 2,336 Shares” was first reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2018/01/03/foundation-medicine-inc-fmi-cfo-jason-ryan-sells-2336-shares.html.
Foundation Medicine Company Profile
Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.
Receive News & Ratings for Foundation Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine and related companies with MarketBeat.com's FREE daily email newsletter.